Skip to content

Opus Genetics IRD Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
$14.03M+213%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$3.11M+120%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$922K+644%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$163.1M+169%
Regenxbio logo
RegenxbioRGNX
$146K-2.7%
Prime Medicine logo
Prime MedicinePRME
$393K

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's stock issuance proceeds?
Opus Genetics (IRD) reported stock issuance proceeds of $2.25M in Q1 2026.
How has Opus Genetics's stock issuance proceeds changed year-over-year?
Opus Genetics's stock issuance proceeds increased by 450.1% year-over-year, from $409K to $2.25M.
What is the long-term trend for Opus Genetics's stock issuance proceeds?
Over 3 years (2021 to 2025), Opus Genetics's stock issuance proceeds has grown at a -41.2% compound annual growth rate (CAGR), from $28.49M to $5.81M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.